X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.onclive.com/view/ropeginterferon-alfa-2b-produces-responses-safety-in-prefibrotic-primary-myelofibrosis
https://endpts.com/pharmaessentia-takes-besremi-rare-blood-cancer-message-to-consumers/
https://www.businesswire.com/news/home/20211112005909/en/U.S.-FDA-Approves-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-the-Only-Interferon-for-Adults-With-Polycythemia-Vera
https://www.businesswire.com/news/home/20201207005234/en/Five-Year-Data-on-Ropeginterferon-Alfa-2b-Illustrate-Durable-Response-at-Five-Years-in-People-With-Polycythemia-Vera
https://www.aoporphan.com/sk_en/our-company/newsroom/aop-orphan-pharmaceuticals-announces-five-year-results-on-besremi-r-ropeginterferon-alfa-2b-in-polycythaemia-vera-at-the-american-society-of-hematology-ash-annual-meeting-2020
Market Place
Share 
